DOI:
10.1055/s-00034916
Nervenheilkunde
LinksClose Window
References
Study group.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Am Heart J 2010;
159: 340-7.
We do not assume any responsibility for the contents of the web pages of other providers.